Bridging Technique with AILEENE Vol. 2 for Softening Nasolabial Folds
Official title: A Prospective Clinical Evaluation of the Bridging Technique Using AILEENE Vol. 2 Dermal Filler for the Treatment of Nasolabial Folds
Run by JNL Aesthetics Limited · NCT07178119 · Data updated 2026-11-12
This study will try the Bridging Technique using very small amounts of AILEENE Vol. 2 filler to soften visible nasolabial folds in adults aged 30 to 65.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 30 Years to 65 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | JNL Aesthetics Limited Academic / other |
| Locations | 1 site (Warrington, Cheshire) |
| Status | Recruiting |
| Started | November 22, 2025 |
| Main results expected | May 2026 |
| Study ends | November 2026 |
| Registry record updated | December 4, 2025 |
| Trial ID | NCT07178119 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 30–65 with visible bilateral nasolabial folds scored ≥2 on the Nasolabial Fold Severity Scale, generally healthy, willing to undergo the Bridging Technique with AILEENE Vol. 2 and to refrain from other facial cosmetic procedures for six months are ideal candidates.
✕Probably not a fit
People with very deep or structural facial volume loss, active facial skin disease, uncontrolled chronic illness, prior extensive facial surgery in the treatment area, or those outside the 30–65 age range may not benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The trial uses a blunt cannula to place thin horizontal threads of hyaluronic acid filler (AILEENE Vol. 2) beneath each nasolabial fold, with each retrograde placement delivering less than 0.05 mL. Treatments are performed bilaterally from a single entry point and aim to provide internal support that lifts and softens the fold while minimizing volume and tissue distortion. Participants receive the Bridging Technique injection and attend structured follow-up visits, including an early virtual safety check and in-person assessments over a six-month period with blinded photographic evaluation and patient-reported outcomes. The protocol is designed to gather systematic safety and effectiveness data to validate the technique beyond anecdotal clinical use.
Why it matters
Potential benefit: If successful, the technique could offer natural-looking reduction of nasolabial folds using smaller filler volumes and potentially lower risk of complications compared with bulk filler placement.
How similar studies have gone: The Bridging Technique has several years of positive real-world clinical use reported by practitioners, but it has not previously been validated in a prospective, structured clinical study.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria Adults aged 30 to 65 years, inclusive, at the time of screening. Male or female, able and willing to comply with study procedures. Presence of visible bilateral nasolabial folds (NLF), each with a score of 2 or higher on the Nasolabial Fold Severity Scale (NLFSS), as assessed by the Principal Investigator. Willing to undergo facial dermal filler treatment using the Bridging Technique with AILEENE Vol. 2. In generally good health, without uncontrolled chronic illness or active skin disease that could interfere with treatment or healing. Able to provide written informed consent and understand the nature and purpose of the study. Willing to refrain from undergoing any other facial cosmetic procedures (e.g., dermal fillers, botulinum toxin, laser, surgery, or radiofrequency) during the six-month study period. Agree to photographic documentation of the treatment area and follow-up assessments, and willing to allow use of anonymized photographs for blinded evaluation and publication. For women of childbearing potential: negative urine pregnancy test at baseline. Female participants of childbearing potential will undergo a urine pregnancy test on the day of treatment as a safety precaution, since there is insufficient evidence on filler safety during pregnancy. Exclusion Criteria Presence of NLF graded less than 2 on the NLFSS on either side of the face. Known allergy or hypersensitivity to hyaluronic acid (HA), lidocaine, or any component of AILEENE Vol. 2. History of severe allergic reactions, anaphylaxis, or allergy to local anesthetics. Prior use of dermal fillers, permanent implants, or other cosmetic procedures in the NLF area or lower face within the past 12 months. Use of botulinum toxin, chemical peels, laser, radiofrequency, or cryotherapy in the mid- or lower face within the last six months. Active skin infection, inflammation, herpes simplex (cold sore), acne, or other dermatologic condition in the treatment area. Use of topical medications such as retinoids or corticosteroids on the face within 30 days prior to treatment. Current or recent use (within 14 days) of anticoagulant, antiplatelet, or non-steroidal anti-inflammatory drugs (NSAIDs) that may increase the risk of bruising or bleeding. History of bleeding disorders.
Where it's running
-
JNL Aesthetics Limited
Warrington, Cheshire, United Kingdom Recruiting
Study contacts
- Principal investigator: Joseph M Novoa Libermann, MBBS — JNL Aesthetics Limited
- Study coordinator: Prof. Joseph M Novoa Libermann, MBBS
- Email: drjoe@jnlaesthetics.com
- Phone: +44 7722260964
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Face photos test to measure biological aging with AI for healthy adults
Researchers will use FaceAge, an AI-based tool that estimates biological age from a frontal face photo, to see how its estimates vary over time in healthy adults and what factors might influence them.
-
One facial acupuncture session to see if it improves skin and how satisfied people are with their look
A single facial rejuvenation acupuncture session is being tested in adults 30–60 to see if it improves skin structure and how happy people are with their appearance.
-
Comparing fractional CO₂ and long‑pulsed 1064‑nm Nd:YAG lasers for skin rejuvenation
This trial will see if fractional CO₂ laser or long‑pulsed 1064‑nm Nd:YAG better improves signs of skin aging in adults aged 30–59 with Glogau II–III.
-
Autologous hair-follicle secretome for facial rejuvenation
This study will test whether injections of your own hair-follicle secretome can improve signs of facial aging in adults aged 30–75.
-
Injectable hyaluronic acid filler for lips, nasolabial folds, and midface volume
The study tests three concentrations of an injectable hyaluronic acid filler to see if it safely and effectively enhances lips, smooths nasolabial folds, and adds midface volume in adults.
-
CelluJuve for moderate to severe Nasolabial Fold Wrinkles
This study tests CelluJuve® to see if it can improve moderate to severe nasolabial folds in adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.